Presented
by

Presented by Oxford Global

Member Login
|
Become a Member

Next Up

Immuno UK: In-Person

29 - 30 September 2022 |

London, UK

29 - 30 September 2022

London, UK

Designing & delivering innovative immunotherapies to transform cancer care.

> Visit Event Website

15 Sep 2022
Thu, 15 September 2022

Advancing the Development of Engineered T-Cell Therapies, from Discovery to the Clinic

Presented by Matthieu Pesant, Senior Market Strategy Manager for Cell & Gene Therapy, Takara Bio

> More Information

03 Oct 2022
Mon, 03 October 2022

Immuno US: In-Person

Discuss the latest strategies to harness the immune system for the development of innovative therapeutics

> Visit Event Website

01 Nov 2022
Tue, 01 November 2022

Tumour Microenvironment: In-Person

> Visit Event Website

12 Dec 2022
Mon, 12 December 2022

Upcoming Immuno Sino Biological Webinar

Presented by Sino Biological

> More Information

> See All Upcoming Oxford Global Immuno Events
> See All Webinars & Recordings

Highlights

Vibha Jawa Featured Image
Discussion Group Report
AAV Gene Therapy and CAR T Therapies: Immunogenicity and Immunoassay Development
Dr. Vibha Jawa, Executive Director, Nonclinical Disposition and Bioanalysis at BMS
Edited by Tom Cohen |
02 August 2022
Translational & Preclinical Development
Commentary
Using Live Gut Bacteria as a Co-Therapy for Checkpoint Inhibitors
19 Jul 2022
Therapeutic Modalities
Insight Article
Microbiome Solutions to Immuno-Oncology Problems
Edited by Tom Cohen |
14 Jul 2022
Therapeutic Modalities

In-Depth

Vibha Jawa Featured Image
Discussion Group Report
AAV Gene Therapy and CAR T Therapies: Immunogenicity and Immunoassay Development
Dr. Vibha Jawa, Executive Director, Nonclinical Disposition and Bioanalysis at BMS
02 August 2022
Gut Microbiome and Probiotics - Association with Gastrointestinal Diseases - Leaky Gut - Dysbiosis - Small Intestinal Bacterial Overgrowth - Conceptual Illustration
Commentary
Using Live Gut Bacteria as a Co-Therapy for Checkpoint Inhibitors
Microbiotica’s live bacterial therapeutic is currently manufacturing for phase Ib trials in 2023.
19 July 2022
colourful 3D render of bacteria in the gut
Insight Article
Microbiome Solutions to Immuno-Oncology Problems
Investigating the role of the microbiota in checkpoint inhibitor response.
14 July 2022
3D Rendering of Molecular Mechanism of T Cell Attack Using Granz
Commentary
Investigating the Core Tenet of Immunotherapy: MHC-I Peptide-Receptor Complexes
Axel Ducret, a Roche Senior Principal Scientist, takes us through his work on one of the most important cellular mechanisms in immunotherapy.
01 July 2022
> See All

[sponsor section - bespoke content]

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Twitter Linkedin-in

Event Series

About

Careers

Legal

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Immuno

> Register